Are Perforator
Flaps Truly More Cost Effective Than TRAM Flaps? How Good
is the Evidence?
Commentary
19 July 2000
Robert Goldwyn, MD
Editor, Plastic and Reconstructive Surgery
1101 Beacon Street
Brookline, MA 02146
Dear Sir,
Thank you for the thoughtful and interesting remarks made
by Carolyn L. Kerrigan and E. Dale Collins in their letter
to the editor, "Are Perforator Flaps Truly More Cost-effective
Than TRAM Flaps? How Good is the Evidence?" The authors
clearly put much time into their lengthy and well-cited letter,
but we're afraid that we cannot agree with their final conclusion.
While the authors made important observations in their letter,
they appear to have missed the point of our article. Our study
was an observational comparison of two institutions with comparable
volumes and surgical experience in two different procedures,
the free perforator flap and the free TRAM flap. In fact,
with regard to experience and volume and its effects on efficiency,
at the time of our study we at LSU had less than five years
experience with the free perforator flap while those at MD
Anderson had well over five years experience with the free
TRAM flap. If anything, we were at a disadvantage. Since that
time, the surgeons at MD Anderson have, in the interests of
optimal patient care, replaced the free TRAM flap with the
free perforator flap. Kerrigan and Collins themselves admit
that while they do dispute our paper, they "do not dispute
that perforator flaps may be more cost effective."
In fact, one reason for the cost-effectiveness is the shorter
stay of patients who have had a perforator flap breast reconstruction.
As stated in our article, the reason for this is that underlying
muscle tissue is left intact in the perforator flap reconstruction,
and the inevitable result is a drastically lowered morbidity
rate in essentially undisturbed tissue. Given this, we would
not be able to support the authors' contention that our study
demonstrates that a shorter stay might be possible for all
free flap breast reconstructions, including those in which
muscle tissue was sacrificed. Instead, we would argue that
like implants before it, the myocutaneous flap breast reconstruction
may be outdated, and should be considered a second-line treatment
for breast reconstruction. Indeed, patients should be informed
of their right to preserve their muscle tissue in autologous
breast reconstruction, and the myocutaneous flap should only
be used when it is necessary to transfer muscle tissue to
restore function. In all other cases, the free perforator
flap breast reconstruction must be considered the new standard
of care.
Robert J. Allen, MD
Constance Chen
4429 Clara Street
Suite 440
New Orleans, LA 70115
.............................................................................................................................
June 02, 2000
Robert Goldwyn, M.D.
Editor, Plastic and Reconstructive Surgery
1101 Beacon Street
Brookline, Mass 02146
Dear Sir,
We cannot agree with the conclusions made by Jonathan Kaplan
and Robert Allen in their paper, "Cost-Based Comparison
between Perforator Flaps and TRAM flaps for Breast Reconstruction
" (Plast. Reconstr. Surg. 105 (3): 943, 2000).(1) Although
there are important conclusions that can be drawn from this
manuscript, they are not the ones suggested by the authors.
Principally, there are serious flaws in their concluding statement
that "this technique should gain credibility and greater
use in breast reconstruction" based on their purported
findings of shorter hospital stay, shorter surgery and thus
lower cost.
Others have developed broad guidelines for rating medical
literature based on study design, allowing readers to weich
the quality of the evidence. Level 1 studies provide the strongest
evidence and level 5 the weakest (Figure 1 (2)). As a case
series, this paper by Kaplan and Allen would be graded as
a level IV study. Further limitations are its retrospective
nature and its lack of a comparison group built into the study
design. While the authors look to the literature for an historical
control, (3) there are inherent flaws in this approach, as
many variables cannot be controlled for. At a minimum, these
uncontrolled variables, which may in themselves account for
any differences seen, should be acknowledged. Therein lies
the weakness in this paper. Although Kaplan and Allen address
and adjust for change in value of the dollar between 1993
and 1997, there are multiple other potential variables that
they fail to enumerate and address. In particular, if the
observed differences in cost are real, then what are the alternative
explanations for these differences? While we regard duration
of surgery and length of hospital stay as reasonable proxies
for cost, there are other factors that must be considered.
Some obvious elements that could account for the observed
differences include:
1. size, composition and expertise of the surgical team
2. working relationship between general surgeon and plastic
surgeon (sequencing of mastectomy and reconstruction)
3. patient selection and presence of comorbidities
4. anesthesia techniques including postoperative pain management
5. variable care paths at different institutions
6. changing attitudes and trends to shortened hospital stay
7. home support by visiting nurses
In their study, Kaplan and Allen based their analysis on
59 DIEP flaps and 5 gluteal artery perforator flaps. The steps
performed in carrying out a free flap breast reconstruction
can be broken into 3 steps: 1. harvesting of the free flap,
2.completion of microsurgical anastomoses and 3. sculpting
of the breast. The latter two are essentially identical between
the TRAM and the DIEP flap. Therefore, it is reasonable to
assume that it is the harvesting of the flap that accounts
for differences in time to complete either approach. The harvest
of these two flaps is quite similar with the exception of
the final step in muscle dissection versus perforator dissection.
In experienced hands, a surgeon is faster at the technique
with which they are most familiar. In learning a new technique,
one goes through a leaning curve to develop equal speed and
efficiency. Having said this, if Kaplan and Allen had data
to compare their own speed at doing TRAM's versus DIEP'S,
we would be surprised if there was a difference in surgical
time of 2 hours.
Other surgeons performing perforator flaps have reported
mean operating 4 times of 6.2 hours (4) and 4.67 hours (5)
for unilateral reconstruction and mean hospital stay of 7.9
days.(4) The experience of both of these authors led to comments
such as "the more complex nature of this type of surgery,
leading to increased operating time" and "the more
tedious flap dissection" These reports emphasize the
known variability in operative times and fallacy inherent
in Kaplan and Allen's conclusion. A more recent abstract from
the senior author's group indicates that their current surgical
time has decreased further to 5.4 hours while their hospital
stay has increased to 4.7 days! (6) Operative times vary by
procedure, however the procedure is but one of many factors
responsible for variations.
Surgical volume is directly correlated with efficiency, speed,
lower complications and better outcomes. This has been demonstrated
in numerous large surgical series, where the relationship
between surgical volume and outcome such as mortality and
complications has been demonstrated convincingly.(7,8) This
has also been demonstrated in our literature where Kroll et.
al. showed shorter operative times and better outcomes later
in their series of free TRAM flaps.(9) It follows that increasing
volume of a given procedure is likely to have an impact on
efficient use of OR time and length of hospital stay. If Kaplan
and Allen chose to compare their experience with that of another
surgeon performing perforator flaps, they would likely have
found differences in duration of surgery and length of stay.
Likewise, if they had chosen high volume surgeons doing TRAM'S,
they may have found the TRAM to take less surgical time and
have a shorter hospital stay than their current practice with
perforator flaps. Anecdotally, we are aware of teams performing
free TRAM breast reconstructions in 4 hours or less, with
hospital stays of 3 days.
We are all aware that more than surgical technique drives
operative time and length of hospital stay. For example, some
general surgeons prefer to complete the mastectomy before
allowing the plastic surgeon to begin the reconstruction,
whereas others encourage flap elevation simultaneously with
the mastectomy It is not clear from the papers being compared
if the sequencing of surgical care is similar. If not, this
alone could account for the difference in duration of surgery
rather than the technique. The size and skill of the surgical
team is also a critical determinant. Most surgeons rely on
trainees or nonphysician surgical assistants in completing,
TRAM'S. We don't know what the full composition of the team
was in this paper, however, there are at least two plastic
surgeons working together on the DIEP flaps. Certainly this
would appear to be a more expensive, but more efficient approach,
than the norm of practice. Yet Kaplan and Allen fail to address
this issue in their analysis. Even if the direct salary costs
were accounted for, the lost opportunity costs would be significant.
Though we cannot agree with the conclusions drawn by Kaplan
and Allen, their work does contribute useful information to
the literature. Firstly, they have established a standard
suggesting that it may be safe to discharge a free flap after
only 3 days of hospitalization. This is in contrast to a style
of practice characterized through the '80's and early '90's
by patients being routinely hospitalized for 7 days (3) and
more recently shortened to 5 days (10). There are even suggestions
that outpatient free flaps may be an option for some indications.(11)
Hwang et. al. implemented a clinical pathway and documented
an ability to shorten hospital stay without incurring an increase
rate of complications.(10) If Kaplan and Allen were to share
the details of the postoperative management of their patients
in the form of a clinical pathway, many of us would likely
benefit. In any case, this report represents a valuable benchmark
for others to work towards.
Secondly, Kaplan and Allen also have set a published benchmark
of 6.2 hours for breast reconstruction with a free flap. However,
it is not clear if the duration reflects their experience
and high volumes, the use of a perforator flap rather than
TRAM, the expertise of the surgeons or support staff, or the
sequencing of simultaneous flap elevation during the mastectomy.
As a group, physicians have a tendency to assume ultimate
responsibility for clinical outcomes. This unjustly minimizes
the importance of the environments in which we work and the
role played by the total care process. Other team members
(anesthesia, hospital nursing staff, community nursing staff,
and family members) and their attitudes also have a profound
influence on the efficiency with which we work and the outcome
of our interventions.
We do not dispute that perforator flaps may be more cost
effective, but we do dispute that this paper produces the
evidence to support that conclusion. The conclusion that these
data support are that indicators of quality care (such as
duration of surgery and length of stay) for similar procedures
can vary widely from institution to institution. The real
service that these authors provided was in demonstratincy
that free flap breast reconstruction can be done with shorter
stay and this should encourage us all to examine our practices
and strive for efficiencies and outcomes that are comparable
to the leaders in our field. The authors are challenged to
come up with more rigorous scientific data to support their
conclusion. In closing, we would like to encourage readers
of the journal to take a careful look at the design of studies
in terms of their quality and weight of evidence before incorporating
new recommendations into their own practice.
Carolyn L. Kerrigan, M.D.
Professor of Surgery
One Medical Center Drive
Lebanon, NH, 03756
carolyn.kerrigan@hitchcock.org
E. Dale Collins, M.D.
Assistant Professor of Surgery
References
1. Allen, R. Cost-Based Comparison between Perforator Flaps
and TRAM flaps for Breast Reconstruction. Plast. Reconstr.
Surg., 105: 943,2000.
2. Anonymous. American Society of Clinical Oncology. Recommendations
for the use of hematopoietic colony-stimulating factors:
evidence-based, clinical practice guidelines. [Review] [256
refs]. Journal of Clinical Oncology, 12: 2471, 1994.
3. Kroll, S. S., Evans, G. R. D., Reece, G. P. et at. Comparison
of resource costs between implant-based and TRAM flap breast
reconstruction. Plast. Reconstr. Surg., 97: 364, 1996.
4. Blondeel, P. N. One hundred free DIEP flap breast reconstructions:
a personal experience. British Journal of Plastic Surgery,
52: 104, 1999.
5. Hamdi, M., Weiler-Mithoff, E. M. and Webster, M. H.
Deep inferior epigastric perforator flap in brest reconstruction:
experience with the first 50 flaps. Plastic & Reconstructive
Surgery, 103:86, 1999.
6. Dupin, C. L., Allen, R. J. and Arnstein, M. R. The deep
inferior epigastric perforator flap for breast reconstruction:
experience with 532 consecutive patients. Paper presented
at the American Association of Plastic Surgeons Annual Meeting,
Laguna Niguel, CA, 2000.
7. Wennberg, D. E., Lucas, F. L., Birkmeyer, J. D., Bredenberg,
C. E. and Fisher, E. S. Variation in carotid endarterectomy
mortality in the Medicare population: trial hospitals, volume,
and patient characteristics [see comments]. JAMA, 279: 278,
1998.
8. Birkmeyer, J. D. High-risk surgery--follow the crowd
[editorial comment JAMA, 283: 1191, 2000.
9. Schusterman, M. A., Kroll, S. S., Miller, M. J. et al.
The free transverse rectus abdominis musculocutaneous flap
for breast reconstruction: one center's experience with
211 consecutive cases. Annals of Plastic Surgery, 32:234,1994.
10. Hwang, T. G., Wilkins, E. G., Lowery, J. C. and Gentile,
J. Implementation and evaluation of a clinical pathway for
TRAM breast reconstruction. Plast Reconstr Surg, 105: 541,
2000.
11. Kutlu, N., Shin, Y.-J., Orbay, J. L., Badia, A. and
Khouri, R. K Outpatient upper extremity free flaps. Paper
presented at the 13th Annual Meeting of the American Society
for Reconstructive Microsurgery Scottsdale, Arizona, 1998.
| Table 1:
LEVELS OF EVIDENCE
(Adapted from the American Society of Clinical Oncology)
2 |
| Level 1 |
Randomized controlled trial or meta
analysis |
| Level 2 |
Excellent experimental study / small
randomized controlled trial |
| Level 3 |
Quasi experimental study / case-control
series |
| Level 4 |
Descriptive and case studies |
| Level 5 |
Case reports / clinical examples |